Torrent Pharmaceuticals Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 5/6
Torrent Pharmaceuticals hat ein Gesamteigenkapital von ₹68.6B und eine Gesamtverschuldung von ₹39.4B, wodurch sich der Verschuldungsgrad auf 57.4% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹150.6B bzw. ₹82.1B. Torrent Pharmaceuticals Das EBIT des Unternehmens beträgt ₹26.2B, so dass der Zinsdeckungsgrad 7.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹9.8B.
Wichtige Informationen
58.9%
Verhältnis von Schulden zu Eigenkapital
₹40.39b
Verschuldung
| Zinsdeckungsgrad | 8.6x |
| Bargeld | ₹10.04b |
| Eigenkapital | ₹68.56b |
| Gesamtverbindlichkeiten | ₹82.04b |
| Gesamtvermögen | ₹150.61b |
Jüngste Berichte zur Finanzlage
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Recent updates
Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Just Reported And Analysts Have Been Lifting Their Price Targets
Jul 26Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More
Mar 02Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?
Feb 10Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?
Jan 19Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: TORNTPHARMDie kurzfristigen Aktiva des Unternehmens (₹56.1B) übersteigen seine kurzfristigen Passiva (₹54.3B).
Langfristige Verbindlichkeiten: TORNTPHARMDie kurzfristigen Vermögenswerte des Unternehmens (₹56.1B) übersteigen seine langfristigen Verbindlichkeiten (₹27.8B).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: TORNTPHARMDie Nettoverschuldung im Verhältnis zum Eigenkapital (43.1%) wird als hoch angesehen.
Schulden abbauen: TORNTPHARM Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 128.1% auf 57.4% zurückgegangen.
Schuldendeckung: TORNTPHARMDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (82.9%).
Zinsdeckung: Die Zinszahlungen für die Schulden von TORNTPHARM sind durch das EBIT gut gedeckt (7.4x coverage).